Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer

Results from INT 0101 (E5188)

Nancy E. Davidson, Anne M. O'Neill, Allen M. Vukov, C. Kent Osborne, Silvana Martino, Douglas R. White, Martin D. Abeloff

Research output: Contribution to journalArticle

Abstract

Purpose: Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established. Patients and Methods: Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT). The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z. Results: With a median follow-up of 9.6 years, the addition of tamoxifen to CAF-Z improved TTR and DFS but not OS. There was no overall advantage for addition of goserelin to CAF. Conclusion: Addition of tamoxifen to CAF-Z improves outcome for premenopausal node-positive, receptor-positive breast cancer. The role of OA/OS alone or with other endocrine agents should be studied more intensely.

Original languageEnglish (US)
Pages (from-to)5973-5982
Number of pages10
JournalJournal of Clinical Oncology
Volume23
Issue number25
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Steroid Receptors
Fluorouracil
Doxorubicin
Cyclophosphamide
Lymph Nodes
Hormones
Breast Neoplasms
Goserelin
Tamoxifen
Therapeutics
Disease-Free Survival
iodonitrotetrazolium
Recurrence
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer : Results from INT 0101 (E5188). / Davidson, Nancy E.; O'Neill, Anne M.; Vukov, Allen M.; Osborne, C. Kent; Martino, Silvana; White, Douglas R.; Abeloff, Martin D.

In: Journal of Clinical Oncology, Vol. 23, No. 25, 2005, p. 5973-5982.

Research output: Contribution to journalArticle

Davidson, Nancy E. ; O'Neill, Anne M. ; Vukov, Allen M. ; Osborne, C. Kent ; Martino, Silvana ; White, Douglas R. ; Abeloff, Martin D. / Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer : Results from INT 0101 (E5188). In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 25. pp. 5973-5982.
@article{e58d250dadb2481c9e41761261dea703,
title = "Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188)",
abstract = "Purpose: Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established. Patients and Methods: Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT). The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z. Results: With a median follow-up of 9.6 years, the addition of tamoxifen to CAF-Z improved TTR and DFS but not OS. There was no overall advantage for addition of goserelin to CAF. Conclusion: Addition of tamoxifen to CAF-Z improves outcome for premenopausal node-positive, receptor-positive breast cancer. The role of OA/OS alone or with other endocrine agents should be studied more intensely.",
author = "Davidson, {Nancy E.} and O'Neill, {Anne M.} and Vukov, {Allen M.} and Osborne, {C. Kent} and Silvana Martino and White, {Douglas R.} and Abeloff, {Martin D.}",
year = "2005",
doi = "10.1200/JCO.2005.05.551",
language = "English (US)",
volume = "23",
pages = "5973--5982",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer

T2 - Results from INT 0101 (E5188)

AU - Davidson, Nancy E.

AU - O'Neill, Anne M.

AU - Vukov, Allen M.

AU - Osborne, C. Kent

AU - Martino, Silvana

AU - White, Douglas R.

AU - Abeloff, Martin D.

PY - 2005

Y1 - 2005

N2 - Purpose: Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established. Patients and Methods: Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT). The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z. Results: With a median follow-up of 9.6 years, the addition of tamoxifen to CAF-Z improved TTR and DFS but not OS. There was no overall advantage for addition of goserelin to CAF. Conclusion: Addition of tamoxifen to CAF-Z improves outcome for premenopausal node-positive, receptor-positive breast cancer. The role of OA/OS alone or with other endocrine agents should be studied more intensely.

AB - Purpose: Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established. Patients and Methods: Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT). The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z. Results: With a median follow-up of 9.6 years, the addition of tamoxifen to CAF-Z improved TTR and DFS but not OS. There was no overall advantage for addition of goserelin to CAF. Conclusion: Addition of tamoxifen to CAF-Z improves outcome for premenopausal node-positive, receptor-positive breast cancer. The role of OA/OS alone or with other endocrine agents should be studied more intensely.

UR - http://www.scopus.com/inward/record.url?scp=24944509667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944509667&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.05.551

DO - 10.1200/JCO.2005.05.551

M3 - Article

VL - 23

SP - 5973

EP - 5982

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -